Tigecycline in Critical Care

Critical Care Clinics

Volumn 24, Issue 2, 2008, Pages 365-375

  Mullangi, Praveen K ^a   Pankey, George A ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CILASTATIN PLUS IMIPENEM; ERTAPENEM; LEVOFLOXACIN; POLYMYXIN B; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; HYPERPIGMENTATION; INTENSIVE CARE; LOADING DRUG DOSE; NAUSEA; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; COSTS AND COST ANALYSIS; CRITICAL CARE; CROSS INFECTION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 40849097545     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.12.007     Document Type: Review

References (34)

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance System (NNIS) report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
2. Eggimann P., and Pittet D. Infection control in ICU. Chest 120 (2001) 2059-2093
3. Klevens M., Edwards J., Richards C., et al. Estimating health care-associated infections and deaths in U.S. Hospitals, 2002. Public Health Rep 122 (2007) 160-166
4. Zhanel G.G., Homenuik K., Nichol K., et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64 1 (2004) 63-88
5. Hirata T., Saito A., Nishino K., et al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 48 6 (2004) 2179-2184
6. Petersen P.J., Jacobus N.V., Weiss W.J., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 (1999) 738-744
7. Pankey G. Tigecycline. J Antimicrob Chemother 56 (2005) 470-480
8. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 43 (2006) 518-524
9. Raad I., Hanna H., Jiang Y., et al. Comparative activities of daptomycin, linezolid and tigecycline against catheter-related methicillin-resistant staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51 5 (2007) 1656-1660
10. Fritsche T., Sader H., Stilwell M., et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 52 (2005) 187-193
11. Hoban D., Bouchillon S., and Dowzicky M. Antimicrobial susceptibility of extended-spectrum beta lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 57 (2007) 423-428
12. Moellering R., Graybill J., McGowan J., et al. Antimicrobial resistance prevention initiative-an update: proceeding of an expert panel on resistance. Am J Med 120 7 (2007) S4-S25
13. Dean C.R., Visalli M.A., Projan S.J., et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47 3 (2003) 972-978
14. Sader H., Jones R., Dowzicky M., et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52 (2005) 203-208
15. Muralidharan G., Micalizzi M., Speth J., et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005) 220-229
16. Cunha B.A. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother 19 (2007) 232-233
17. Wyeth. Clinical trial number: NCT 00366249. Available at: http://www.clinicaltrials.gov.
18. Wart V., Owen J., Ludwig E., et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 50 11 (2006) 3701-3707
19. Conte J.E., Golden J.A., Kelly M.G., et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 25 6 (2005) 523-529
20. Slover C., Rodvold K., and Danziger L. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother 41 (2007) 965-972
21. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 (2005) S341-S353
22. Babinchak T., Ellis-Grosse E.J., Dartois N., et al. The efficacy and safety of tigecycline for the treatment of complicated intra abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 (2005) S354-S366
23. Wyeth Pharmaceuticals. Data on file, Study 308 (CSR-63128).
24. Wyeth Pharmaceuticals. Data on file, Study 313 (CSR-61261).
25. Dukart G., Dartois N., Cooper C., et al. Integrated results of 2 phase 3 studies comparing tigecycline with levofloxacin in patients with community-acquired pneumonia. [abstract] (2006), ICAAC, San Francisco (CA)
26. Knueppel R., and Rahimian J. Diffuse cutaneous hyperpigmentation due to tigecycline and polymyxin B. J. Clin Infect Dis 45 (2007) 136-137
27. Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther 4 4 (2006) 601-618
28. Peleg A., Adams J., and Paterson D. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 51 6 (2007) 2065-2069
29. Rello J. Bench-to-bedside review: therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Crit Care 9 (2005) 259-265
30. Reid G., Grim S., Aldeza C., et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27 8 (2007) 1198-2001
31. Wickens J., Warr C., Jespon A., et al. An outbreak of multi-drug resistant Acinetobacter baumannii infections on an intensive care unit (ICU), and treatment with tigecycline. [abstract]. American Society for Microbiology (2006) 357
32. Schaffer J.J., Goff D.A., Stevenson K.B., et al. Experience with tigecycline for multi-drug resistant Acinetobacter baumannii ventilator-associated pneumonia and bacteremia. [abstract]. American Society for Microbiology (2006) 357
33. Venezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59 (2007) 772-774
34. Medication costs as calculated from information on website. Available at: www.rxusawholesale.com.